Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
-
New drug cocktail aims to outsmart tough lung cancer
Disease control OngoingThis study is testing whether combining two or three different drugs is safe and effective for treating advanced non-small cell lung cancer with a specific genetic mutation called KRAS G12C. It is for adults whose cancer has progressed after prior treatments, including some who h…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug duo tested in fight against recurrent ovarian cancer
Disease control OngoingThis study is testing the safety and effectiveness of a two-drug combination (avutometinib and defactinib) for Japanese patients with recurrent low-grade ovarian cancer. The goal is to see if this treatment can shrink tumors and control the disease. It is for patients whose cance…
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New Four-Drug attack on deadly pancreatic cancer enters human testing
Disease control OngoingThis study is testing a new combination of four drugs for people with metastatic pancreatic cancer who have not yet received any treatment. The main goals are to find the safest and most effective dose of the new drug pair (avutometinib and defactinib) when added to two standard …
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC